Welcome to our dedicated page for NovoCure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NovoCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NovoCure's regulatory disclosures and financial reporting.
Novocure Limited reported second-quarter 2026 net revenues of $183.6 million, a 16% increase year-over-year, with gross margin rising to 78% from 74%. The quarter remained loss-making, with a net loss of $15.7 million or $0.13 per share, but Adjusted EBITDA turned positive at $10.8 million.
Total active patients on Tumor Treating Fields therapy reached 5,128 globally, including 4,636 on Optune Gio, 207 on Optune Lua and 285 on Optune Pax. Cash, cash equivalents and short-term investments totaled $440.6 million as of June 30, 2026, against total liabilities of $457.1 million.
The company received a CE Mark for Optune Pax for locally advanced pancreatic cancer, with Germany as the first launch market, and updated 2026 guidance to $710 million–$725 million in net revenue and $0–$15 million in Adjusted EBITDA. Anticipated Q4 2026 milestones include a U.S. FDA decision on a premarket approval application for brain metastases from non-small cell lung cancer and completion of enrollment in the Phase 3 KEYNOTE D58 glioblastoma trial.
NovoCure Limited reported Q2 2026 net revenues of $183.6 million, up 16% year over year, and first‑half revenues of $357.6 million. Gross margin improved to 78%. Net loss narrowed to $15.7 million in Q2 and $86.8 million for the first half.
Cash, cash equivalents and short‑term investments totaled $440.6 million at June 30, 2026, against $200.0 million of senior secured term debt. Adjusted EBITDA turned positive at $10.8 million in Q2. Active patients on therapy rose to 5,128, driven mainly by Optune Gio.
During the period, the FDA approved Optune Pax for locally advanced pancreatic cancer and a CE certificate was obtained to market it in the EU. The METIS and PANOVA‑4 trials met key endpoints, while the TRIDENT trial in newly diagnosed GBM did not improve overall survival. The company notes it may need to raise additional capital as it expands indications.
NovoCure Ltd reported that its Chief Human Resources Officer, Michal Nath Puri, acquired additional equity through an employee share plan. On June 30, 2026, Puri received 1,905 ordinary shares under the 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, a price determined as 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, as provided by the plan. Following this transaction, Puri directly holds 203,227 ordinary shares of NovoCure. The filing notes that this ESPP transaction is exempt under Rule 16b-3(c), reflecting a routine, compensation-related share acquisition rather than an open-market trade.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X acquired 1,905 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, based on 85% of the closing price on January 1, 2026. Following this ESPP acquisition, he directly holds 461,425 ordinary shares. The transaction is described as exempt under Rule 16b-3(c).
NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at 85% of the January 1, 2026 closing price, at a reported price of $11.15 per share, bringing his direct holdings to 243,752 shares.
NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company’s 2025 Employee Share Purchase Plan (ESPP). The shares were purchased for $11.15 per share for the ESPP purchase period from January 1, 2026 through June 30, 2026.
Under the ESPP, the purchase price was set at 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, making this a routine compensation-related acquisition rather than an open-market trade. Following this transaction, Danziger directly owns 416,742 ordinary shares.
Novocure reported that its wearable device Optune Pax, which delivers Tumor Treating Fields, has received a CE Mark to treat adult patients with locally advanced pancreatic cancer of exocrine origin when used with gemcitabine and nab-paclitaxel in line with guideline recommendations. The approval is backed by the Phase 3 PANOVA-3 trial, where patients in the intent-to-treat group receiving Optune Pax plus chemotherapy achieved a median overall survival of 16.2 months versus 14.2 months on chemotherapy alone, and a significant 6.1‑month extension in median time to pain progression. In the modified intent-to-treat group, median overall survival reached 18.3 months with Optune Pax versus 15.1 months on chemotherapy alone. Optune Pax was generally well-tolerated, with mainly mild to moderate skin events and no device-related deaths reported.
Novocure reported topline data from its Phase 3 TRIDENT trial in newly diagnosed glioblastoma. The study tested starting Tumor Treating Fields (TTFields) at the beginning of chemoradiation versus starting during the maintenance phase.
The trial did not show a statistically significant improvement in the primary endpoint of overall survival for early initiation. Median overall survival in the intent-to-treat group was 17.7 months in the Early Start Arm versus 17.5 months in the Maintenance Start Arm (HR 0.953; p=0.519). One-, two- and three-year survival rates were similar between arms.
TTFields therapy, including initiation with chemoradiation, was well-tolerated with no new safety signals, and device-related safety remained consistent with prior TTFields studies in glioblastoma. Results have been accepted for presentation at the ASTRO 2026 Annual Meeting.
NovoCure Limited held its annual general meeting of shareholders, where investors re-elected eleven directors to serve until the 2027 meeting. Shareholders representing 93,826,730 ordinary shares, or approximately 81.01% of shares entitled to vote, were present in person or by proxy.
They approved the ratification of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as auditor for the fiscal year ending December 31, 2026, and supported executive compensation in a non-binding advisory vote. Shareholders also approved the Company’s Amended and Restated 2024 Omnibus Incentive Plan following a closely split vote between shares cast for and against.